Artificial city

Leveraging Artificial Intelligence (AI) in Egypt: Collaborating to Improve Breast Cancer Outcomes

Download logo

More than 20 years ago, Baheya Wahbi, a member of a prominent Egyptian family, was diagnosed with breast cancer. She found she couldn’t get the care she needed in Egypt, forcing her to travel to the United States and Europe for treatment. While abroad, she worried about the many other Egyptian women with breast cancer who had no resources to travel.

This concern stayed with her and so, before her death, she asked her sons and daughters to buy and bring to Egypt the state-of-the-art radiotherapy machine she could access when she was in the stranger. They agreed, but did even more. Instead of bringing a single machine, they decided to honor their mother and her vision to help other women in Egypt by creating an entire hospital in her name.

Located on the site of her house, the Baheya Foundation hospital is now dedicated to the prevention, early diagnosis and treatment of women with breast cancer. To ensure that all women in Egypt have access to world-class care, the hospital provides its services free of charge.

The foundation and hospital was established in 2015 and currently provides over 7,000 early breast cancer screenings and 1,500 chemotherapy sessions per month, and 3,000 radiation therapy sessions per month in addition to 350 surgeries per month. These numbers will increase significantly when a new branch of the hospital opens in 2023 in Sheikh Zayed west of Cairo.

“In addition to providing direct care to women, Baheya also conducts research to continuously improve the services it offers,” said Dr. Mohamed Emara, CEO of Baheya Hospital. As Baheya is a center of excellence providing the most advanced technology with high reputation companies to keep pace with global development as a unique hospital in Egypt and the MENA region.

Most recently, this includes a collaborative program with GE Healthcare that builds on GE Healthcare’s experience in women’s health, artificial intelligence (AI) and contrast-enhanced spectral mammography (CESM), and Baheya’s clinical expertise in breast imaging.

Under a recently announced agreement, the two partners will work to develop and validate the use of AI to assess and predict the response of neoadjuvant chemotherapy in locally advanced breast cancer.

“We are excited about how this research collaboration has the potential to transform future outcomes for breast cancer patients,” said Agnes Berzsenyi, President and CEO of Women’s Health at GE Healthcare. . By combining our expertise with that of the Baheya Foundation and layering it with AI, we are getting closer to our mission to increase early detection and help save more lives.

Professor Mohamed Gomaa, consultant in radiodiagnostics and head of the radiology department of the Baheya Center for the early detection and treatment of breast cancer, added: “As part of our commitment to continue research in this field, our collaboration with GE Healthcare aims to deploy the power of AI combined with clinical experience to expand our knowledge of neoadjuvant therapy treatment pathways to improve patient outcomes in Baheya and beyond.

Various diagnostic imaging technologies are currently used to predict and assess a patient’s response to neoadjuvant therapy, and AI has the potential to give clinicians an earlier indication that a patient is not responding to a given treatment regimen. , thus allowing for a timely change of treatment. The result would be a reduction in unnecessary toxicity for the patient and a lower treatment cost for the hospital.

The project will explore the use of AI in the CESM to assess the response to neoadjuvant chemotherapy in advanced breast cancer as an accurate indicator and predictor of response that mimics postoperative pathologic outcomes and can accurately predict the percentage residual tumours.

In patients with locally advanced breast cancer, neoadjuvant therapy is used before surgery to help reduce the size of a cancerous tumor. Initially targeted at patients whose cancer is not eligible for surgery, the uses of neoadjuvant therapy have expanded to include patients whose cancers are operable but would be more amenable to surgery after this therapy.

As the Baheya Foundation expands its business and increases the number of patients it serves, this collaboration with GE Healthcare also aims to expand clinical treatment options and further improve patient outcomes and experiences.

Distributed by APO Group on behalf of GE Healthcare.

Follow GE Healthcare on:
Knowledge: for the latest news, or
Visit our website for more information.

Follow Baheya Foundation/Hospital on:

About GE Healthcare:
GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE). As a global leader in medical technology, pharmaceutical diagnostics and digital solutions innovation, GE Healthcare empowers clinicians to make faster, more informed decisions through smart devices, data analytics, apps and services, supported by its Edison intelligence platform. With over 100 years of experience in the healthcare industry and approximately 47,000 employees worldwide, the company operates at the center of an ecosystem driving precision health, digitizing healthcare, helping to drive the productivity and improve outcomes for patients, providers, health systems and researchers around the world.

About Baheya Foundation/Hospital:
Baheya foundation as a leading women’s health NGO was established in 2015 and consists of 6 floors and devices, we have received over 180,000 women so far for early detection and all stages of treatment as a center of excellence.

The Baheya center is proud to announce that it has been accredited by (JCI), the highest accreditation for quality of care, this accreditation proves the willingness of all medical, technical and administrative staff to fully comply with international health standards and recommendations.

Our vision: The Baheya Foundation is the premier destination for women’s health and safety.

Our message: We are an association that offers innovative programs specializing in awareness, early detection and treatment of breast cancer, and psychological support for women using the latest technologies and qualified medical and administrative staff.

Baheya Hospital in Zayed/Giza city as the largest breast cancer hospital will be operated in the first quarter of 2023 with 35000 square meters in 7 floors with all services of the oncology hospital

This press release was issued by APO. Content is not vetted by the African Business editorial team and none of the content has been verified or validated by our editorial teams, proofreaders or fact checkers. The issuer is solely responsible for the content of this announcement.